Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Leukemia

Free Subscription 09.09.2019 2 Am J Hematol 3 Ann Hematol 2 Blood 1 BMC Cancer 7 Bone Marrow Transplant 1 Cancer 1 Exp Hematol 2 Genes Chromosomes Cancer 1 Int J Hematol 2 Leuk Lymphoma 1 Leuk Res 7 Leukemia 1 Oncogene 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Hematol

1. FLINN IW, Cherry MA, Maris MB, Matous JV, et al
   Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia.
   Am J Hematol. 2019 Sep 6. doi: 10.1002/ajh.25634.
   PubMed     Text format     Abstract available
   
   
2. TU S, Huang R, Guo Z, Deng L, et al
   Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CRES or severe CRS.
   Am J Hematol. 2019 Sep 5. doi: 10.1002/ajh.25630.
   PubMed     Text format    
   
   

   
   Ann Hematol

3. WU X, Wang H, Deng J, Zheng X, et al
   Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
   Ann Hematol. 2019 Sep 3. pii: 10.1007/s00277-019-03774.
   PubMed     Text format     Abstract available
   
   
4. QIN YZ, Jiang Q, Xu LP, Jiang H, et al
   The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
   Ann Hematol. 2019 Sep 6. pii: 10.1007/s00277-019-03789.
   PubMed     Text format     Abstract available
   
   
5. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
   Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
   Ann Hematol. 2019 Sep 5. pii: 10.1007/s00277-019-03775.
   PubMed     Text format     Abstract available
   
   

   
   Blood

6. STEPHENS DM
   Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia.
   Blood. 2019 Sep 5. pii: blood.2019001750. doi: 10.1182/blood.2019001750.
   PubMed     Text format     Abstract available
   
   
7. BROUX M, Prieto C, Demeyer S, Vanden Bempt M, et al
   Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
   Blood. 2019 Sep 6. pii: blood.2019000015. doi: 10.1182/blood.2019000015.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. BERGER E, Delpierre C, Despas F, Bertoli S, et al
   Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients.
   BMC Cancer. 2019;19:883.
   PubMed     Text format     Abstract available
   
   

   
   Bone Marrow Transplant

9. BROWNBACK KR, Pitts LR, Abhyankar S
   Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.
   Bone Marrow Transplant. 2018 Apr 26. pii: 10.1038/s41409-018-0182.
   PubMed     Text format    
   
   
10. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed     Text format    
    
    
11. LINDEMANN M, Eiz-Vesper B, Steckel NK, Tischer S, et al
    Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0209.
    PubMed     Text format    
    
    
12. TKACZYK ER, Chen F, Wang J, Gandelman JS, et al
    Overcoming human disagreement assessing erythematous lesion severity on 3D photos of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0211.
    PubMed     Text format    
    
    
13. SHADMAN M, Maloney DG, Storer B, Sandmaier BM, et al
    Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
    Bone Marrow Transplant. 2019 Sep 3. pii: 10.1038/s41409-019-0660.
    PubMed     Text format     Abstract available
    
    
14. EL FAKIH R, Kotb A, Hashmi S, Chaudhri N, et al
    Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0667.
    PubMed     Text format     Abstract available
    
    
15. XU J, Zhao R, Yang L, Gong H, et al
    Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0666.
    PubMed     Text format    
    
    

    
    Cancer

16. ZEIDAN AM, Podoltsev NA, Wang X, Bewersdorf JP, et al
    Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis.
    Cancer. 2019 Sep 4. doi: 10.1002/cncr.32439.
    PubMed     Text format     Abstract available
    
    

    
    Exp Hematol

17. ANTELOPE O, Vellore N, Pomicter AD, Patel AB, et al
    BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia.
    Exp Hematol. 2019 Sep 4. pii: S0301-472X(19)30950.
    PubMed     Text format     Abstract available
    
    

    
    Genes Chromosomes Cancer

18. VOSBERG S, Greif PA
    Clonal evolution of acute myeloid leukemia from diagnosis to relapse.
    Genes Chromosomes Cancer. 2019 Sep 3. doi: 10.1002/gcc.22806.
    PubMed     Text format     Abstract available
    
    
19. CHOPRA M, Bohlander SK
    The cell of origin and the leukemia stem cell in acute myeloid leukemia.
    Genes Chromosomes Cancer. 2019 Aug 31. doi: 10.1002/gcc.22805.
    PubMed     Text format     Abstract available
    
    

    
    Int J Hematol

20. TAKAHASHI T, Usuki K, Matsue K, Ohno H, et al
    Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
    Int J Hematol. 2019 Aug 31. pii: 10.1007/s12185-019-02727.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

21. NAGAI Y, Tsukamoto S, Hino Y, Isshiki Y, et al
    Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 5:1-4. doi: 10.1080/10428194.2019.1660973.
    PubMed     Text format    
    
    
22. LANVERS-KAMINSKY C, Niemann A, Eveslage M, Beck J, et al
    Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 3:1-8. doi: 10.1080/10428194.2019.1658099.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Res

23. KRUZOVA L, Schneiderova P, Holzerova M, Vatolikova M, et al
    Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
    Leuk Res. 2019;85:106218.
    PubMed     Text format     Abstract available
    
    

    
    Leukemia

24. ZHANG Z, Li L, Wu C, Yin G, et al
    Inhibition of Slug effectively targets leukemia stem cells via the Slc13a3/ROS signaling pathway.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0566.
    PubMed     Text format     Abstract available
    
    
25. AZADNIV M, Myers JR, McMurray HR, Guo N, et al
    Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0568.
    PubMed     Text format     Abstract available
    
    
26. BARTH J, Abou-El-Ardat K, Dalic D, Kurrle N, et al
    LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Leukemia. 2019;33:1411-1426.
    PubMed     Text format     Abstract available
    
    
27. LYNCH JR, Salik B, Connerty P, Vick B, et al
    JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
    Leukemia. 2019;33:1400-1410.
    PubMed     Text format     Abstract available
    
    
28. DUBOIS A, Furstoss N, Calleja A, Zerhouni M, et al
    LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
    Leukemia. 2019;33:1501-1513.
    PubMed     Text format     Abstract available
    
    
29. SAENZ DT, Fiskus W, Manshouri T, Mill CP, et al
    Targeting nuclear beta-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Leukemia. 2019;33:1373-1386.
    PubMed     Text format     Abstract available
    
    
30. EFFICACE F, Stagno F, Iurlo A, Breccia M, et al
    Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Leukemia. 2019 Sep 2. pii: 10.1038/s41375-019-0563.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

31. JI D, Zhang P, Ma W, Fei Y, et al
    Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34(+) cells via pre-B-cell leukemia homeobox 1.
    Oncogene. 2019 Sep 5. pii: 10.1038/s41388-019-0998.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

32. GE C, Huang H, Huang F, Yang T, et al
    Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
    Proc Natl Acad Sci U S A. 2019 Sep 5. pii: 1908998116.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: